Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Takako Eguchi Nakajima"'
Autor:
Takako Kaneyasu, Eri Hoshino, Mariko Naito, Yoshimi Suzukamo, Kikuko Miyazaki, Satomi Kojima, Takuhiro Yamaguchi, Takashi Kawaguchi, Tempei Miyaji, Takako Eguchi Nakajima, Kojiro Shimozuma
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Over the past few decades, patient-reported outcomes (PROs) have been used to understand patient health conditions better. Therefore, numerous PRO measures (questionnaires) and guidelines or guidance have been developed. However,
Externí odkaz:
https://doaj.org/article/1c9806dc31ff4258a448935bda916335
Autor:
Takako Kaneyasu, Shinya Saito, Kikuko Miyazaki, Yoshimi Suzukamo, Mariko Naito, Takashi Kawaguchi, Takako Eguchi Nakajima, Takuhiro Yamaguchi, Kojiro Shimozuma
Publikováno v:
Health and Quality of Life Outcomes, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Patient-reported outcomes (PROs) are frequently used in a variety of settings, including clinical trials and clinical practice. The definition of PRO and quality of life (QOL) and their relationship have been concluded through discussions am
Externí odkaz:
https://doaj.org/article/cb8c4916615d470bab9f3312f4a5d799
Autor:
Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D. Danenberg, Narikazu Boku, Takako Eguchi Nakajima
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Background Long‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FO
Externí odkaz:
https://doaj.org/article/f1dd28fe734a4a8888bd792971f6399b
Autor:
Yasutoshi Kuboki, Takako Eguchi Nakajima, Takafumi Koyama, Eriko Sumi, Kotaro Suzuki, Agnish Dey, Hideaki Kagehara, Petar Pop-Damkov, Eiki Maeda, Takenori Akaike, Kondala Atkuri, Masashi Ochi, Ganesh M Mugundu, Aman Singh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2a19b131d9514d939273cfdd5ff527fa
Autor:
Shun Yamamoto, Kengo Nagashima, Takeshi Kawakami, Seiichiro Mitani, Masato Komoda, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama, Kentaro Yamazaki, Toshiki Masuishi, Taito Esaki, Takako Eguchi Nakajima, Hiroyuki Okuda, Toshikazu Moriwaki, Narikazu Boku
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months.
Externí odkaz:
https://doaj.org/article/ffc380b74963483f8c6fa47268c6861c
Autor:
Hiroyuki Arai, Satoru Iwasa, Narikazu Boku, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Keiko Minashi, Shuichi Hironaka, Naoki Fukuda, Daisuke Takahari, Takako Eguchi Nakajima
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background There is no standard first-line chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Although fluoropyrimidine is often used, its efficacy is limited, and it remains unclear whether combination therapy with
Externí odkaz:
https://doaj.org/article/84fcec85faaf40e8956c431946702505
Autor:
Takako Eguchi Nakajima, Chikatoshi Katada, Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, Honda Kazunori, Yusuke Inada, Hitoshi Arioka, Hajime Morita, Naoya Hida, Mitsuhiro Sugawara, Shuichi Nawata, Hiroo Ishida, Takashi Tsuda
Publikováno v:
BMJ Open, Vol 10, Iss 12 (2020)
Introduction Dexamethasone (DEX) is administered for multiple days to prevent chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy (HEC); however, its notorious side effects have been widely reported. Althoug
Externí odkaz:
https://doaj.org/article/b035f200f8874e499b4b1025fbd8bd51
Autor:
Hideaki Bando, Atsushi Ohtsu, Takayuki Yoshino, Toshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, Yoshito Komatsu, Eiji Shinozaki, Takako Eguchi Nakajima, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Masashi Wakabayashi, Shogo Nomura, Koji Takahashi, Hiromi Ono, Nami Hirano, Noriko Fujishiro, Nozomu Fuse, Akihiro Sato
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
Background BRAF V600E mutations are associated with aggressive biology and limited response to standard chemotherapy, especially during second-line and beyond therapies. BRAF V600E mutant and wild-type colorectal cancers (CRCs) differ in their expres
Externí odkaz:
https://doaj.org/article/d4dc360f8caa4a12beca9ac3e971093a
Autor:
Hiroyuki Arai, Takako Eguchi Nakajima
Publikováno v:
Cancers, Vol 12, Iss 5, p 1100 (2020)
Gastric cancer (GC) is a molecularly heterogeneous disease. Its molecular background, epidemiology, and standard of care are quite different between Eastern and Western countries. Many efforts have been made in developing more effective surgeries and
Externí odkaz:
https://doaj.org/article/6c4a5402398041409e343bb6b0ad5630
Autor:
Toshio, Shimizu, Takako Eguchi, Nakajima, Noboru, Yamamoto, Kan, Yonemori, Takafumi, Koyama, Shunsuke, Kondo, Yu, Sunakawa, Naoki, Izawa, Yoshiki, Horie, Silong, Xiang, Siying, Xu, Lan, Qin, John, Gong, David, Liu
Publikováno v:
Investigational New Drugs. 40:1021-1031
Envafolimab is the first and only globally approved subcutaneously injectable PD-L1 antibody. This open-label, multicenter Phase 1 trial assessed the safety, tolerability, pharmacokinetic (PK) profile, and efficacy of envafolimab as a single agent in